069620.KS KSC
Daewoong pharmaceutical Co.,Ltd
1W: +2.6%
1M: -14.0%
3M: -7.9%
YTD: -39.1%
1Y: -18.7%
3Y: +13.3%
5Y: -37.1%
₩109,000.00 ($81.03)
-600.00 (-0.55%)
Weekly Expected Move ±4.8%
₩98556
₩103778
₩109000
₩114222
₩119444
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$2.36T
+19.5% ▲
5Y CAGR: +11.6%
Total Liabilities
$1.23T
+17.0% ▲
5Y CAGR: +12.8%
Shareholders Equity
$1.01T
+26.6% ▲
5Y CAGR: +12.8%
Cash & Investments
$172.8B
+48.5% ▲
5Y CAGR: -0.5%
Total Debt
$829.4B
+27.7% ▲
5Y CAGR: +13.2%
Net Debt
$660.4B
+20.9% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $75.9B | $103.0B | $111.5B | $103.0B | $168.9B |
| Short-Term Investments | $97.8B | $37.7B | $26.2B | $13.4B | $3.9B |
| Cash & ST Investments | $173.7B | $140.7B | $137.7B | $116.3B | $172.8B |
| Net Receivables | $162.2B | $185.7B | $184.0B | $214.7B | $233.3B |
| Inventory | $175.1B | $208.7B | $241.5B | $256.4B | $310.9B |
| Other Current Assets | $2.9B | $1.6B | -$2.9B | $1.6B | $3.5B |
| Total Current Assets | $520.4B | $549.0B | $574.8B | $612.8B | $732.4B |
| Property, Plant & Equip. | $395.9B | $440.9B | $521.9B | $675.7B | $842.3B |
| Goodwill & Intangibles | $225.2B | $266.0B | $297.5B | $346.7B | $367.5B |
| Long-Term Investments | $20.5B | $108.6B | $292.4B | $167.3B | $325.9B |
| Other Non-Current Assets | $190.1B | $134.7B | $12.4B | $105.7B | $16.1B |
| Total Non-Current Assets | $890.3B | $1.01T | $1.20T | $1.36T | $1.63T |
| Total Assets | $1.42T | $1.56T | $1.77T | $1.98T | $2.36T |
| — Liabilities — | |||||
| Accounts Payable | $70.9B | $83.4B | $101.1B | $83.0B | $106.2B |
| Short-Term Debt | $256.0B | $233.7B | $369.2B | $321.5B | $277.9B |
| Deferred Revenue | $132.8B | $23.5B | $0 | $0 | $24.8B |
| Other Current Liabilities | -$12.0B | $110.4B | $35.2B | $95.3B | $151.2B |
| Total Current Liabilities | $460.7B | $472.8B | $626.3B | $629.4B | $588.8B |
| Long-Term Debt | $181.7B | $204.8B | $65.0B | $324.5B | $550.6B |
| Other Non-Current Liab. | $21.3B | $104.7B | $50.7B | $57.6B | $71.6B |
| Total Non-Current Liabilities | $252.1B | $349.3B | $162.5B | $420.6B | $639.3B |
| Total Liabilities | $712.8B | $822.1B | $858.0B | $1.05T | $1.23T |
| — Equity — | |||||
| Common Stock | $29.0B | $29.0B | $29.0B | $29.0B | $29.0B |
| Retained Earnings | $471.1B | $504.3B | $647.8B | -$4.1B | $157.6B |
| Accumulated OCI | $431.9B | -$28.5B | -$26.9B | $0 | $669.7B |
| Total Stockholders Equity | $573.6B | $608.0B | $803.0B | $794.6B | $1.01T |
| Total Liabilities & Equity | $1.42T | $1.56T | $1.77T | $1.98T | $2.36T |
| — Key Metrics — | |||||
| Total Debt | $445.7B | $446.7B | $436.7B | $649.2B | $829.4B |
| Net Debt | $369.8B | $343.8B | $419.5B | $546.3B | $660.4B |
| Total Investments | $118.4B | $146.3B | $318.6B | $180.7B | $329.8B |